Comparative Pharmacology
Head-to-head clinical analysis: ISENTRESS versus JULUCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISENTRESS versus JULUCA.
ISENTRESS vs JULUCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of HIV-1 integrase, blocking strand transfer step of retroviral DNA integration into host genome.
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing integration of viral DNA into host chromosomal DNA. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via incorporation into viral DNA, causing chain termination.
400 mg orally twice daily.
One tablet orally once daily, each tablet containing dolutegravir 50 mg and rilpivirine 25 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 7–12 hours; no significant accumulation with twice-daily dosing.
Dolutegravir: ~14 hours (terminal; supports once-daily dosing). Lamivudine: ~13-19 hours (terminal; supports once-daily dosing; prolonged in renal impairment).
Renal (approximately 51% as unchanged drug via glomerular filtration and active tubular secretion) and fecal (approximately 32% as unchanged drug).
Dolutegravir: 64% fecal (as unchanged drug), 32% renal (as glucuronide conjugate); <1% unchanged in urine. Lamivudine: 70% renal (as unchanged drug) via glomerular filtration and active tubular secretion; 5-10% as trans-sulfoxide metabolite.
Category C
Category C
HIV Integrase Inhibitor
HIV Integrase Inhibitor / NNRTI Combination